<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38690875</PMID><DateCompleted><Year>2024</Year><Month>06</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN><JournalIssue CitedMedium="Internet"><Volume>98</Volume><Issue>6</Issue><PubDate><Year>2024</Year><Month>Jun</Month><Day>13</Day></PubDate></JournalIssue><Title>Journal of virology</Title><ISOAbbreviation>J Virol</ISOAbbreviation></Journal><ArticleTitle>Pharmacological activation of TLR7 exerts inhibition on the replication of EV-D68 in respiratory cells.</ArticleTitle><Pagination><StartPage>e0043424</StartPage><MedlinePgn>e0043424</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e00434-24</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/jvi.00434-24</ELocationID><Abstract><AbstractText>The globally reemerging respiratory pathogen enterovirus D68 (EV-D68) is implicated in outbreaks of severe respiratory illness and associated with acute flaccid myelitis. However, there remains a lack of effective treatments for EV-D68 infection. In this work, we found that the host Toll-like receptor 7 (TLR7) proteins, which function as powerful innate immune sensors, were selectively elevated in expression in response to EV-D68 infection. Subsequently, we investigated the impact of Vesatolimod (GS-9620), a Toll-like receptor 7 agonist, on EV-D68 replication. Our findings revealed that EV-D68 infection resulted in increased mRNA levels of TLR7. Treatment with Vesatolimod significantly inhibited EV-D68 replication [half maximal effective concentration (EC<sub>50</sub>) = 0.1427 µM] without inducing significant cytotoxicity at virucidal concentrations. Although Vesatolimod exhibited limited impact on EV-D68 attachment, it suppressed RNA replication and viral protein synthesis after virus entry. Vesatolimod broadly inhibited the replication of circulating isolated strains of EV-D68. Furthermore, our findings demonstrated that treatment with Vesatolimod conferred resistance to both respiratory and neural cells against EV-D68 infection. Overall, these results present a promising strategy for drug development by pharmacologically activating TLR7 to initiate an antiviral state in EV-D68-infected cells selectively.IMPORTANCEConventional strategies for antiviral drug development primarily focus on directly targeting viral proteases or key components, as well as host proteins involved in viral replication. In this study, based on our intriguing discovery that enterovirus D68 (EV-D68) infection specifically upregulates the expression of immune sensor Toll-like receptor 7 (TLR7) protein, which is either absent or expressed at low levels in respiratory cells, we propose a potential antiviral approach utilizing TLR7 agonists to activate EV-D68-infected cells into an anti-viral defense state. Notably, our findings demonstrate that pharmacological activation of TLR7 effectively suppresses EV-D68 replication in respiratory tract cells through a TLR7/MyD88-dependent mechanism. This study not only presents a promising drug candidate and target against EV-D68 dissemination but also highlights the potential to exploit unique alterations in cellular innate immune responses induced by viral infections, selectively inducing a defensive state in infected cells while safeguarding uninfected normal cells from potential adverse effects associated with therapeutic interventions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Huili</ForeName><Initials>H</Initials><Identifier Source="ORCID">0009-0007-3135-2358</Identifier><AffiliationInfo><Affiliation>Institute of Virology and AIDS Research, First Hospital, Jilin University, Changchun, Jilin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yuehan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute of Virology and AIDS Research, First Hospital, Jilin University, Changchun, Jilin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Qingran</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Institute of Virology and AIDS Research, First Hospital, Jilin University, Changchun, Jilin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhe</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Institute of Virology and AIDS Research, First Hospital, Jilin University, Changchun, Jilin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Siyu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Virology and AIDS Research, First Hospital, Jilin University, Changchun, Jilin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Haoran</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Virology and AIDS Research, First Hospital, Jilin University, Changchun, Jilin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Wei</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0003-4456-840X</Identifier><AffiliationInfo><Affiliation>Institute of Virology and AIDS Research, First Hospital, Jilin University, Changchun, Jilin, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education, Institute of Translational Medicine, First Hospital, Jilin University, Changchun, Jilin, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>32222005, 82372226</GrantID><Agency>MOST | National Natural Science Foundation of China (NSFC)</Agency><Country /></Grant><Grant><GrantID>82172246</GrantID><Agency>MOST | National Natural Science Foundation of China (NSFC)</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Virol</MedlineTA><NlmUniqueID>0113724</NlmUniqueID><ISSNLinking>0022-538X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051199">Toll-Like Receptor 7</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495348">TLR7 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>O8M467C50G</RegistryNumber><NameOfSubstance UI="C582524">vesatolimod</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007211">Indoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011621">Pteridines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051199" MajorTopicYN="Y">Toll-Like Receptor 7</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="Y">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D030016" MajorTopicYN="Y">Enterovirus D, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053586" MajorTopicYN="N">Virus Internalization</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011621" MajorTopicYN="N">Pteridines</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">MyD88</Keyword><Keyword MajorTopicYN="N">TLR7</Keyword><Keyword MajorTopicYN="N">Vesatolimod/GS-9620</Keyword><Keyword MajorTopicYN="N">antivirals</Keyword><Keyword MajorTopicYN="N">enterovirus D68</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>13</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>5</Month><Day>1</Day><Hour>13</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>5</Month><Day>1</Day><Hour>9</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38690875</ArticleId><ArticleId IdType="pmc">PMC11237570</ArticleId><ArticleId IdType="doi">10.1128/jvi.00434-24</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Morrey JD, Wang H, Hurst BL, Zukor K, Siddharthan V, Van Wettere AJ, Sinex DG, Tarbet EB. 2018. Causation of acute flaccid paralysis by myelitis and myositis in enterovirus-D68 infected mice deficient in interferon αβ/γ receptor deficient mice. Viruses 10:33. doi:10.3390/v10010033</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v10010033</ArticleId><ArticleId IdType="pmc">PMC5795446</ArticleId><ArticleId IdType="pubmed">29329211</ArticleId></ArticleIdList></Reference><Reference><Citation>Greninger AL, Naccache SN, Messacar K, Clayton A, Yu G, Somasekar S, Federman S, Stryke D, Anderson C, Yagi S, Messenger S, Wadford D, Xia D, Watt JP, Van Haren K, Dominguez SR, Glaser C, Aldrovandi G, Chiu CY. 2015. A novel outbreak enterovirus D68 strain associated with acute flaccid myelitis cases in the USA (2012-14): a retrospective cohort study. Lancet Infect Dis 15:671–682. doi:10.1016/S1473-3099(15)70093-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(15)70093-9</ArticleId><ArticleId IdType="pmc">PMC6027625</ArticleId><ArticleId IdType="pubmed">25837569</ArticleId></ArticleIdList></Reference><Reference><Citation>Schieble JH, Fox VL, Lennette EH. 1967. A probable new human picornavirus associated with respiratory diseases. Am J Epidemiol 85:297–310. doi:10.1093/oxfordjournals.aje.a120693</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfordjournals.aje.a120693</ArticleId><ArticleId IdType="pubmed">4960233</ArticleId></ArticleIdList></Reference><Reference><Citation>Midgley CM, Jackson MA, Selvarangan R, Turabelidze G, Obringer E, Johnson D, Giles BL, Patel A, Echols F, Oberste MS, Nix WA, Watson JT, Gerber SI. 2014. Severe respiratory illness associated with enterovirus D68 - Missouri and Illinois, 2014. MMWR Morb Mortal Wkly Rep 63:798–799.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4584696</ArticleId><ArticleId IdType="pubmed">25211545</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggen J, Thibaut HJ, Strating JRPM, van Kuppeveld FJM. 2018. The life cycle of non-polio enteroviruses and how to target it. Nat Rev Microbiol 16:368–381. doi:10.1038/s41579-018-0005-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-018-0005-4</ArticleId><ArticleId IdType="pubmed">29626210</ArticleId></ArticleIdList></Reference><Reference><Citation>Elrick MJ, Pekosz A, Duggal P. 2021. Enterovirus D68 molecular and cellular biology and pathogenesis. J Biol Chem 296:100317. doi:10.1016/j.jbc.2021.100317</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2021.100317</ArticleId><ArticleId IdType="pmc">PMC7949111</ArticleId><ArticleId IdType="pubmed">33484714</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Sheng J, Fokine A, Meng G, Shin WH, Long F, Kuhn RJ, Kihara D, Rossmann MG. 2015. Structure and inhibition of EV-D68, a virus that causes respiratory illness in children. Science 347:71–74. doi:10.1126/science.1261962</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1261962</ArticleId><ArticleId IdType="pmc">PMC4307789</ArticleId><ArticleId IdType="pubmed">25554786</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Yue, Sheng J, Baggen J, Meng G, Xiao C, Thibaut HJ, van Kuppeveld FJM, Rossmann MG. 2015. Sialic acid-dependent cell entry of human enterovirus D68. Nat Commun 6:8865. doi:10.1038/ncomms9865</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms9865</ArticleId><ArticleId IdType="pmc">PMC4660200</ArticleId><ArticleId IdType="pubmed">26563423</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei W, Guo H, Chang J, Yu Y, Liu G, Zhang N, Willard SH, Zheng S, Yu XF. 2016. ICAM-5/telencephalin is a functional entry receptor for enterovirus D68. Cell Host Microbe 20:631–641. doi:10.1016/j.chom.2016.09.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2016.09.013</ArticleId><ArticleId IdType="pubmed">27923705</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei X, Xiao X, Wang J. 2016. Innate immunity evasion by enteroviruses: insights into virus-host interaction. Viruses 8:22. doi:10.3390/v8010022</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v8010022</ArticleId><ArticleId IdType="pmc">PMC4728582</ArticleId><ArticleId IdType="pubmed">26784219</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Li J, Li Q. 2018. Immune evasion of enteroviruses under innate immune monitoring. Front Microbiol 9:1866. doi:10.3389/fmicb.2018.01866</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2018.01866</ArticleId><ArticleId IdType="pmc">PMC6102382</ArticleId><ArticleId IdType="pubmed">30154774</ArticleId></ArticleIdList></Reference><Reference><Citation>Musharrafieh R, Ma C, Zhang J, Hu Y, Diesing JM, Marty MT, Wang J. 2019. Validating enterovirus D68-2Apro as an antiviral drug target and the discovery of telaprevir as a potent D68-2Apro inhibitor. J Virol 93:e02221-18. doi:10.1128/JVI.02221-18</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02221-18</ArticleId><ArticleId IdType="pmc">PMC6430540</ArticleId><ArticleId IdType="pubmed">30674624</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost J, Rudy MJ, Leser JS, Tan H, Hu Y, Wang J, Clarke P, Tyler KL. 2023. Telaprevir treatment reduces paralysis in a mouse model of enterovirus D68 acute flaccid myelitis. J Virol 97:e0015623. doi:10.1128/jvi.00156-23</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.00156-23</ArticleId><ArticleId IdType="pmc">PMC10231134</ArticleId><ArticleId IdType="pubmed">37154751</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma C, Hu Y, Zhang J, Wang J. 2020. Pharmacological characterization of the mechanism of action of R523062, a promising antiviral for enterovirus D68. ACS Infect Dis 6:2260–2270. doi:10.1021/acsinfecdis.0c00383</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsinfecdis.0c00383</ArticleId><ArticleId IdType="pmc">PMC8057299</ArticleId><ArticleId IdType="pubmed">32692536</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Kitamura N, Musharrafieh R, Wang J. 2021. Discovery of potent and broad-spectrum pyrazolopyridine-containing antivirals against enteroviruses D68, A71, and coxsackievirus B3 by targeting the viral 2C protein. J Med Chem 64:8755–8774. doi:10.1021/acs.jmedchem.1c00758</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.1c00758</ArticleId><ArticleId IdType="pmc">PMC9179928</ArticleId><ArticleId IdType="pubmed">34085827</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas A, Laxton C, Rodman J, Myangar N, Horscroft N, Parkinson T. 2007. Investigating toll-like receptor agonists for potential to treat hepatitis C virus infection. Antimicrob Agents Chemother 51:2969–2978. doi:10.1128/AAC.00268-07</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00268-07</ArticleId><ArticleId IdType="pmc">PMC1932540</ArticleId><ArticleId IdType="pubmed">17548497</ArticleId></ArticleIdList></Reference><Reference><Citation>Braun H, Kirchmair J, Williamson MJ, Makarov VA, Riabova OB, Glen RC, Sauerbrei A, Schmidtke M. 2015. Molecular mechanism of a specific capsid binder resistance caused by mutations outside the binding pocket. Antiviral Res 123:138–145. doi:10.1016/j.antiviral.2015.09.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2015.09.009</ArticleId><ArticleId IdType="pubmed">26391975</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramaswamy M, Tummala R, Streicher K, Nogueira da Costa A, Brohawn PZ. 2021. The pathogenesis, molecular mechanisms, and therapeutic potential of the interferon pathway in systemic lupus erythematosus and other autoimmune diseases. Int J Mol Sci 22:11286. doi:10.3390/ijms222011286</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms222011286</ArticleId><ArticleId IdType="pmc">PMC8540355</ArticleId><ArticleId IdType="pubmed">34681945</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Z, Zheng H, Li H, Chen Y, Hou D, Fan Q, Song J, Guo L, Liu L. 2021. The expression of IFN-β is suppressed by the viral 3D polymerase via its impact on PGAM5 expression during enterovirus D68 infection. Virus Res 304:198549. doi:10.1016/j.virusres.2021.198549</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2021.198549</ArticleId><ArticleId IdType="pubmed">34425164</ArticleId></ArticleIdList></Reference><Reference><Citation>Rui Y, Su J, Wang H, Chang J, Wang S, Zheng W, Cai Y, Wei W, Gordy JT, Markham R, Kong W, Zhang W, Yu XF. 2017. Disruption of MDA5-mediated innate immune responses by the 3C proteins of coxsackievirus A16, coxsackievirus A6, and enterovirus D68. J Virol 91. doi:10.1128/JVI.00546-17</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00546-17</ArticleId><ArticleId IdType="pmc">PMC5469270</ArticleId><ArticleId IdType="pubmed">28424289</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown DM, Hixon AM, Oldfield LM, Zhang Y, Novotny M, Wang W, Das SR, Shabman RS, Tyler KL, Scheuermann RH. 2018. Contemporary circulating enterovirus D68 strains have acquired the capacity for viral entry and replication in human neuronal cells. mBio 9. doi:10.1128/mBio.01954-18</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.01954-18</ArticleId><ArticleId IdType="pmc">PMC6191546</ArticleId><ArticleId IdType="pubmed">30327438</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y-L, Guo Y-J, Bin L, Sun S-H. 2009. Hepatitis C virus single-stranded RNA induces innate immunity via toll-like receptor 7. J Hepatol 51:29–38. doi:10.1016/j.jhep.2009.03.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2009.03.012</ArticleId><ArticleId IdType="pubmed">19443072</ArticleId></ArticleIdList></Reference><Reference><Citation>Crozat K, Beutler B. 2004. TLR7: a new sensor of viral infection. Proc Natl Acad Sci U S A 101:6835–6836. doi:10.1073/pnas.0401347101</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0401347101</ArticleId><ArticleId IdType="pmc">PMC406426</ArticleId><ArticleId IdType="pubmed">15123819</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggen J, Thibaut HJ, Staring J, Jae LT, Liu Y, Guo H, Slager JJ, de Bruin JW, van Vliet ALW, Blomen VA, Overduin P, Sheng J, de Haan CAM, de Vries E, Meijer A, Rossmann MG, Brummelkamp TR, van Kuppeveld FJM. 2016. Enterovirus D68 receptor requirements unveiled by haploid genetics. Proc Natl Acad Sci U S A 113:1399–1404. doi:10.1073/pnas.1524498113</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1524498113</ArticleId><ArticleId IdType="pmc">PMC4747778</ArticleId><ArticleId IdType="pubmed">26787879</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi O, Akira S. 2010. Pattern recognition receptors and inflammation. Cell 140:805–820. doi:10.1016/j.cell.2010.01.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2010.01.022</ArticleId><ArticleId IdType="pubmed">20303872</ArticleId></ArticleIdList></Reference><Reference><Citation>Koutsogiannaki S, Bu W, Maisat W, Manzor M, Zhang Z, Ohto U, Eckenhoff RG, Yuki K. 2022. Propofol directly binds to and inhibits TLR7. FASEB J 36:e22481. doi:10.1096/fj.202200312R</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.202200312R</ArticleId><ArticleId IdType="pmc">PMC9382702</ArticleId><ArticleId IdType="pubmed">35899460</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu CF, Peng WM, Schlee M, Barchet W, Eis-Hübinger AM, Kolanus W, Geyer M, Schmitt S, Steinhagen F, Oldenburg J, Novak N. 2018. SOCS1 and SOCS3 target IRF7 degradation to suppress TLR7-mediated type I IFN production of human plasmacytoid dendritic cells. J Immunol 200:4024–4035. doi:10.4049/jimmunol.1700510</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1700510</ArticleId><ArticleId IdType="pubmed">29712772</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Liu M, Guo X, Zhang B, Li H, Liu Y, Han J, Jia L, Li L. 2022. Endogenous retrovirus elements are co-expressed with IFN stimulation genes in the JAK-STAT pathway. Viruses 15:60. doi:10.3390/v15010060</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15010060</ArticleId><ArticleId IdType="pmc">PMC9861321</ArticleId><ArticleId IdType="pubmed">36680099</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawai T, Akira S. 2011. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 34:637–650. doi:10.1016/j.immuni.2011.05.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2011.05.006</ArticleId><ArticleId IdType="pubmed">21616434</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasperczyk H, La Ferla-Brühl K, Westhoff MA, Behrend L, Zwacka RM, Debatin K-M, Fulda S. 2005. Betulinic acid as new activator of NF-kappaB: molecular mechanisms and implications for cancer therapy. Oncogene 24:6945–6956. doi:10.1038/sj.onc.1208842</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1208842</ArticleId><ArticleId IdType="pubmed">16007147</ArticleId></ArticleIdList></Reference><Reference><Citation>Fulda S, Kroemer G. 2009. Targeting mitochondrial apoptosis by betulinic acid in human cancers. Drug Discov Today 14:885–890. doi:10.1016/j.drudis.2009.05.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2009.05.015</ArticleId><ArticleId IdType="pubmed">19520182</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Musharrafieh R, Zheng M, Wang J. 2020. Enterovirus D68 antivirals: past, present, and future. ACS Infect Dis 6:1572–1586. doi:10.1021/acsinfecdis.0c00120</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsinfecdis.0c00120</ArticleId><ArticleId IdType="pmc">PMC8055446</ArticleId><ArticleId IdType="pubmed">32352280</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J, Hu XY, Yu XF. 2019. Current understanding of human enterovirus D68. Viruses 11:490. doi:10.3390/v11060490</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v11060490</ArticleId><ArticleId IdType="pmc">PMC6631698</ArticleId><ArticleId IdType="pubmed">31146373</ArticleId></ArticleIdList></Reference><Reference><Citation>Helfferich J, de Lange MM, Benschop KS, Jacobs BC, Van Leer-Buter CC, Meijer A, Bakker DP, de Bie E, Braakman HM, Brandsma R, Neuteboom RF, Niks EH, Niermeijer J-M, Roelfsema V, Schoenmaker N, Sie LT, Niesters HG, Brouwer OF, Te Wierik MJ. 2022. Epidemiology of acute flaccid myelitis in children in the Netherlands, 2014 to 2019. Euro Surveill 27:2200157. doi:10.2807/1560-7917.ES.2022.27.42.2200157</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2022.27.42.2200157</ArticleId><ArticleId IdType="pmc">PMC9585879</ArticleId><ArticleId IdType="pubmed">36268734</ArticleId></ArticleIdList></Reference><Reference><Citation>Boni C, Vecchi A, Rossi M, Laccabue D, Giuberti T, Alfieri A, Lampertico P, Grossi G, Facchetti F, Brunetto MR, Coco B, Cavallone D, Mangia A, Santoro R, Piazzolla V, Lau A, Gaggar A, Subramanian GM, Ferrari C. 2018. TLR7 agonist increases responses of hepatitis B virus-specific T cells and natural killer cells in patients with chronic hepatitis B treated with Nucleos(T)Ide analogues. Gastroenterology 154:1764–1777. doi:10.1053/j.gastro.2018.01.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2018.01.030</ArticleId><ArticleId IdType="pubmed">29378197</ArticleId></ArticleIdList></Reference><Reference><Citation>Riddler SA, Para M, Benson CA, Mills A, Ramgopal M, DeJesus E, Brinson C, Cyktor J, Jacobs J, Koontz D, Mellors JW, Laird GM, Wrin T, Patel H, Guo S, Wallin J, Boice J, Zhang L, Humeniuk R, Begley R, German P, Graham H, Geleziunas R, Brainard DM, SenGupta D. 2021. Vesatolimod, a toll-like receptor 7 agonist, induces immune activation in virally suppressed adults living with human immunodeficiency virus-1. Clin Infect Dis 72:e815–e824. doi:10.1093/cid/ciaa1534</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1534</ArticleId><ArticleId IdType="pubmed">33043969</ArticleId></ArticleIdList></Reference><Reference><Citation>Baccala R, Hoebe K, Kono DH, Beutler B, Theofilopoulos AN. 2007. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med 13:543–551. doi:10.1038/nm1590</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1590</ArticleId><ArticleId IdType="pubmed">17479100</ArticleId></ArticleIdList></Reference><Reference><Citation>Petes C, Odoardi N, Gee K. 2017. The toll for trafficking: toll-like receptor 7 delivery to the endosome. Front Immunol 8:1075. doi:10.3389/fimmu.2017.01075</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01075</ArticleId><ArticleId IdType="pmc">PMC5591332</ArticleId><ArticleId IdType="pubmed">28928743</ArticleId></ArticleIdList></Reference><Reference><Citation>Giltiay NV, Chappell CP, Sun X, Kolhatkar N, Teal TH, Wiedeman AE, Kim J, Tanaka L, Buechler MB, Hamerman JA, Imanishi-Kari T, Clark EA, Elkon KB. 2013. Overexpression of TLR7 promotes cell-intrinsic expansion and autoantibody production by transitional T1 B cells. J Exp Med 210:2773–2789. doi:10.1084/jem.20122798</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20122798</ArticleId><ArticleId IdType="pmc">PMC3832927</ArticleId><ArticleId IdType="pubmed">24145511</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang J, Huang M, Li J, Zhang K, Zhu C, Liu S, Zhou Z, Wang T, Wang Z. 2023. Enterovirus D68 VP3 targets the interferon regulatory factor 7 to inhibit type I interferon response. Microbiol Spectr 11:e0413822. doi:10.1128/spectrum.04138-22</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/spectrum.04138-22</ArticleId><ArticleId IdType="pmc">PMC10269600</ArticleId><ArticleId IdType="pubmed">37125923</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin T, He S, Wang Y. 2015. Toll-like receptor 7/8 agonist, R848, exhibits antitumoral effects in a breast cancer model. Mol Med Rep 12:3515–3520. doi:10.3892/mmr.2015.3885</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2015.3885</ArticleId><ArticleId IdType="pubmed">26043701</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou BB, Wang F, Li L, Cheng FW, Jin R, Luo X, Zhu LX, Geng X, Zhang SQ. 2015. Activation of toll-like receptor 7 inhibits the proliferation and migration, and induces the apoptosis of pancreatic cancer cells. Mol Med Rep 12:6079–6085. doi:10.3892/mmr.2015.4130</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2015.4130</ArticleId><ArticleId IdType="pubmed">26238718</ArticleId></ArticleIdList></Reference><Reference><Citation>Zúñiga LA, Leßmann T, Uppal K, Bisek N, Hong E, Rasmussen CE, Karlsson JJ, Zettler J, Holten-Andersen L, Bang K, et al. . 2022. Intratumoral delivery of TransCon(TM) TLR7/8 agonist promotes sustained anti-tumor activity and local immune cell activation while minimizing systemic cytokine induction. Cancer Cell Int 22:286. doi:10.1186/s12935-022-02708-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12935-022-02708-6</ArticleId><ArticleId IdType="pmc">PMC9484246</ArticleId><ArticleId IdType="pubmed">36123697</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Mercier I, Poujol D, Sanlaville A, Sisirak V, Gobert M, Durand I, Dubois B, Treilleux I, Marvel J, Vlach J, Blay JY, Bendriss-Vermare N, Caux C, Puisieux I, Goutagny N. 2013. Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment. Cancer Res 73:4629–4640. doi:10.1158/0008-5472.CAN-12-3058</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-12-3058</ArticleId><ArticleId IdType="pubmed">23722543</ArticleId></ArticleIdList></Reference><Reference><Citation>Amin OE, Colbeck EJ, Daffis S, Khan S, Ramakrishnan D, Pattabiraman D, Chu R, Micolochick Steuer H, Lehar S, Peiser L, Palazzo A, Frey C, Davies J, Javanbakht H, Rosenberg WMC, Fletcher SP, Maini MK, Pallett LJ. 2021. Therapeutic potential of TLR8 agonist GS-9688 (Selgantolimod) in chronic hepatitis B: remodeling of antiviral and regulatory mediators. Hepatology 74:55–71. doi:10.1002/hep.31695</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.31695</ArticleId><ArticleId IdType="pmc">PMC8436741</ArticleId><ArticleId IdType="pubmed">33368377</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>